Gilead CEO sells 15,000 shares in planned trade

Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock.

Rhea-AI Filing Summary

Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock. On July 1, 2026, he sold 3,100 shares at an average price of $127.075 and 11,900 shares at $126.0897, according to the Form 4.

The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, indicating they were pre-arranged rather than newly timed decisions. Footnotes state sale prices for the reported transactions ranged from $125.59 to $127.44, with full trade-by-trade details available on request.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 2 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 15,000 shs ($1.89M)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,900	$126.0897	$1.50M
Sale	Common Stock	3,100	$127.075	$394K

Holdings After Transaction: Common Stock — 607,133 shares (Direct)

Footnotes (3)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
2. F2. Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. F3. Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold (total): 15,000 shares First sale: 3,100 shares at $127.075 Second sale: 11,900 shares at $126.0897 +1 more

4 metrics

Shares sold (total) 15,000 shares Total open-market sales reported on July 1, 2026

First sale 3,100 shares at $127.075 Common Stock, open-market sale on July 1, 2026

Second sale 11,900 shares at $126.0897 Common Stock, open-market sale on July 1, 2026

Price range $125.59–$127.44 Footnote range for reported sale prices

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for each Common Stock transaction."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" for both non-derivative transactions."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gilead Sciences (GILD) report for CEO Daniel O'Day?

Gilead Sciences reported that Chairman & CEO Daniel O'Day sold 15,000 shares of Common Stock. The Form 4 shows two open-market sales on July 1, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026.

How many Gilead (GILD) shares did Daniel O'Day sell in this Form 4?

Daniel O'Day sold a total of 15,000 Gilead shares. The filing details two separate open-market sales: 3,100 shares and 11,900 shares of Common Stock, both on July 1, 2026, as part of an established Rule 10b5-1 trading plan.

At what prices did Gilead CEO Daniel O'Day sell his GILD shares?

The reported sales occurred at average prices of $127.075 and $126.0897 per share. Footnotes add that transaction prices ranged from $125.59 to $127.44, with full trade-by-trade price and size details available to regulators, the company, or shareholders upon request.

Was Daniel O'Day’s Gilead (GILD) share sale part of a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were made under a Rule 10b5-1 trading plan adopted on February 25, 2026. Such plans pre-schedule trades, which can indicate the timing of sales was set in advance rather than based on recent developments.

What type of transaction is reported for Gilead (GILD) CEO Daniel O'Day?

The Form 4 reports open-market sales of Gilead Common Stock by Daniel O'Day. Both entries use transaction code "S," described as a sale in the open market or private transaction, and are categorized as non-derivative transactions involving the company’s Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		11,900	D	$126.0897(2)	610,233	D
Common Stock	07/01/2026		S(1)		3,100	D	$127.075(3)	607,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)